Skip to content
Aminoscope
← Research
Peptides

Sermorelin before and after: what the evidence actually shows

Sermorelin’s real, trial-documented “before and after” is faster growth in GH-deficient children. The dramatic adult transformation photos have no controlled outcome trials behind them.

Julian Roth6 min read
DOCUMENTEDpediatric growth, measured in trialsheightyear 1therapy beginsMARKETEDadult “before / after” transformationbeforeafter(no outcome trial)SERMORELIN (GHRH 1-29) · A REAL “BEFORE / AFTER” EXISTS — JUST NOT THE ONE BEING SOLD

Sermorelin has no documented adult “before and after” transformation. In a 6-week trial of nightly sermorelin in 11 older men, growth-hormone pulses rose but IGF-1, muscle and fat did not change. In a 16-week trial of a close analog, IGF-1 rose within 2 weeks, lean mass rose in men only, and sleep did not change.[4][5]

How long does sermorelin take to work? A week-by-week read of the trials

The table below lines up what adult studies of sermorelin (GHRH 1-29) and its close analog actually measured at each time point, against what transformation marketing promises for the same window. Where no adult trial measured something, the table says so.

Sermorelin timeline: what the studies measured versus what is marketed
Time pointWhat the studies measured (IGF-1, sleep, body composition)What is marketed
First dose to week 2A nightly dose of a sermorelin analog released a GH pulse within 10 minutes that lasted about 2 hours; serum IGF-1 was higher by week 2 (n = 19 adults aged 55–71).Deeper sleep and more energy within days
Week 6Nightly sermorelin 2 mg in 11 men aged 64–76 (n = 11): nocturnal GH rose, but IGF-1, weight, and DEXA muscle and fat did not change; 2 of 6 strength measures improved.Visible fat loss and muscle tone
Week 12In the 16-week analog trial, IGF-1 was still elevated at week 12.A leaner, younger-looking body
Week 16IGF-1 drifted back toward baseline; lean body mass rose in men only; no other body-composition or bone change; self-rated sleep quality unchanged in both sexes; nitrogen balance improved (P = 0.03, combined).A full body transformation
6 to 12 monthsNo adult trial data. The only long-run record is pediatric: height velocity in GH-deficient children rose from 4.1 to 8.0 cm/yr at six months.Sustained anti-aging results
Sermorelin timeline: what the studies measured versus what is marketed Vittone et al., Metabolism 1997 (PMID 9005976); Khorram et al., J Clin Endocrinol Metab 1997 (PMID 9141536); Thorner et al., J Clin Endocrinol Metab 1996 (PMID 8772599).

Two caveats keep the table honest. The 16-week study used [Nle27]GHRH(1-29), a stabilized analog of sermorelin, not the compounded product sold today; and both adult trials were small (n = 11 and n = 19), short and run in older adults with an age-related dip in the GH axis.[4][5] Neither measured the visible change that before-and-after photos show.

Searches for “sermorelin before and after” almost always expect the same thing: a side-by-side photo of a leaner, more muscular, younger-looking adult after a few months of nightly injections. It is worth saying plainly at the top — that specific transformation has no controlled outcome trial behind it. There is a genuine, documented “before and after” in sermorelin’s record, but it comes from its approved-drug era and looks nothing like a physique reveal. This page explains what real, measured sermorelin results actually are, why the dramatic adult claims aren’t backed by trials, and what an honest expectation looks like.

The real, trial-documented “before and after”

Sermorelin is GHRH 1-29, the active fragment of growth-hormone-releasing hormone. In its approved-drug era it was used to evaluate and treat children with growth-hormone deficiency, and that is where its one well-documented before-and-after lives. A multicenter study by the Geref International Study Group found that once-daily subcutaneous GHRH therapy accelerated growth in GH-deficient children during the first year of treatment: across 110 previously untreated prepubertal children, mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at six months and 7.2 cm/yr at twelve, with 74% judged good responders at six months.[1] Contemporary reviews of sermorelin summarized this pediatric growth effect, alongside its diagnostic stimulation-test role, as the established, evidence-backed use of the molecule.[2] That is the authentic “after”: a deficient child growing faster, documented on a growth chart, in a defined trial population.

Notice how different that is from the marketed promise. The documented result is about restoring growth in someone who was deficient, it was measured with an objective endpoint (height velocity), and it played out over a year of daily injections under specialist care — not a body-recomposition montage in a healthy adult.

What does a measured sermorelin effect look like?

The honest, mechanism-level “result” you can expect from sermorelin is a biochemical one: by prompting the pituitary to release a pulse of growth hormone, it can raise GH and, downstream, IGF-1. That is the lever it pulls, and it is real. But moving a hormone level on a lab report is not the same as the visible transformation people picture. A “before and after” on a blood panel — a higher IGF-1 number — is the kind of change with documented support; a “before and after” in the mirror is the kind being marketed without it. Even the most favorable published framing of sermorelin in adults presented it as a question — a possible approach to adult-onset GH insufficiency — and a rationale, not as a body-transformation therapy with before-and-after outcomes to show.[3]

Do sermorelin before-and-after photos show real results?

The transformation photos circulating today come from a separate world: off-label, compounded or “research”-channel sermorelin sold to healthy adults for “anti-aging” and GH-optimization. There is no FDA-approved sermorelin product for those uses and — critically — no body of randomized outcome trials showing that nightly injections in healthy adults produce measurable fat loss, muscle gain, or a younger appearance. A photo is not an endpoint. The change you see in a before-and-after image could come from a simultaneous diet change, training, lighting, water weight, photo selection, or simply the placebo-rich enthusiasm of starting a new regimen — none of which the peptide can claim credit for in the absence of a controlled comparison. We walk through the full state of the adult evidence in our sermorelin evidence review.

Slow, variable, and easy to over-attribute

Even taking the most charitable view, anything sermorelin does works through your own GH axis, which means it is inherently slow and variable. Any GH-axis effect depends on your baseline, your age, your pituitary’s responsiveness, sleep, and other factors — so two people on the same protocol can see very different (or no) measurable change. That variability is exactly what makes cherry-picked before-and-after images so misleading: the most dramatic result gets posted, the unremarkable ones never do. And because the documented dosing for sermorelin belongs to the pediatric and diagnostic era, there is no validated adult protocol to anchor expectations to in the first place — the dosing history is laid out in our sermorelin dosage overview, and the plausible downsides in our sermorelin side effects page.

The honest bottom line

Sermorelin does have a real “before and after” — faster growth in growth-hormone-deficient children, measured in trials, over a year of therapy.[1] What it does not have is the dramatic adult body-recomposition or anti-aging transformation that “before and after” searches are hoping to find: there are no controlled outcome trials in healthy adults to support it. The defensible, evidence-based result is biochemical and modest — a possible rise in GH and IGF-1 — not a guaranteed change in how you look. If you are considering sermorelin and your real question is “will I get a transformation,” the truthful answer is that no one can promise one from the published record. The appropriate next step is a conversation with a qualified clinician, not a dose and a hoped-for photo copied from a forum.

Reviewed against primary sources by the Aminoscope desk

Sources

  1. [1] Thorner M, Rochiccioli P, Colle M, Lanes R, et al.; Geref International Study Group. (1996). Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab. PMID 8772599
  2. [2] Prakash A, Goa KL. (1999). Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. PMID 18031173
  3. [3] Walker RF. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. PMID 18046908
  4. [4] Vittone J, Blackman MR, Busby-Whitehead J, et al. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. PMID 9005976
  5. [5] Khorram O, Laughlin GA, Yen SS. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. PMID 9141536

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Provider reviews we publish: Heros HealthPeter MDMadeMedShedLive VitalSystem Labs

Related tool

Peptide evidence matrix

See every peptide graded by how strong the human evidence actually is — filter by evidence tier, with a primary source on each grade.

More in Peptides